Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00183742 · ClinicalTrials.gov registry record · Phase 1
Trial of Liposomal Doxorubicin (Doxil) and Weekly Docetaxel (Taxotere)
A Phase 1 study, sponsored by University of Southern California.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT00183742 is a Phase 1 study that has completed, run by University of Southern California. The registered enrollment target is 35 participants.
The verdict
NCT00183742, a Phase 1 study, has completed, sponsored by University of Southern California.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
This study is for patients with advanced cancer that has failed treatment with conventional therapy or for which no standard treatment exists. The purpose of this study is to determine the highest dose that can be given of 2 chemotherapy drugs, docetaxel (also called Taxotere) and liposomal doxorubicin (also called Doxil), when given together and to determine the side effects of this combination. Both Taxotere and Doxil are chemotherapy drugs that can decrease the size of several different tumors. Taxotere is approved by the Food and Drug Administration (FDA) for the treatment of breast and lung cancers, and Doxil is approved for the treatment of ovarian cancer.
Interventions
- DRUG liposomal doxorubicin and docetaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2000-12 |
| Est. Completion | 2006-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00183742
The ClinicalTrials.gov registry entry for NCT00183742 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which liposomal doxorubicin and docetaxel is the first listed.
NCT00183742 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00183742 about?
NCT00183742 is a clinical study titled "Trial of Liposomal Doxorubicin (Doxil) and Weekly Docetaxel (Taxotere)". This study is for patients with advanced cancer that has failed treatment with conventional therapy or for which no standard treatment exists. The purpose of this study is to determine the highest dose that can be given of 2 chemotherapy drugs, docetaxel (also called Taxotere) and liposomal doxorubi...
What is the current status of trial NCT00183742?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2000-12. Estimated completion is 2006-05.
What interventions are being tested in trial NCT00183742?
The interventions under investigation include: liposomal doxorubicin and docetaxel (DRUG).
Who is sponsoring clinical trial NCT00183742?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.